Clinical trials
Recurrent or Metastatic Nasopharyngeal Carcinoma clinical trials
Below are recruiting recurrent or metastatic nasopharyngeal carcinoma clinical trials, each written for real people, not researchers. We’re tracking 2,385 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT07492641RecruitingPhase 3
A new drug plus letrozole for advanced HR+ breast cancer
This trial tests a new medicine (BGB-43395) combined with letrozole against the usual CDK4/6 inhibitor plus letrozole. It is for people with advanced or metastatic HR-positive, HER2-negative breast cancer who have not yet had treatment for advanced disease.
Birmingham, AlabamaAges 18 years+ - NCT07029256Recruiting
Ultrasound-guided biopsy for bladder cancer staging
This trial uses an ultrasound-guided needle biopsy to check if bladder cancer has spread beyond the bladder. It may help doctors stage the cancer more accurately before surgery.
Rochester, MinnesotaAges 18 years+ - NCT07082439RecruitingPhase 2
Pembrolizumab and Odetiglucan for Liver-Dominant Colorectal Cancer
This study tests a combination of two drugs, pembrolizumab and odetiglucan, in people whose colorectal cancer has spread mainly to the liver and has not responded to standard treatments. The goal is to see if this combination can shrink or slow the growth of liver tumors.
Philadelphia, PennsylvaniaAges 18 years+ - NCT06957626Recruiting
Predicting polyp return after removal
This study aims to develop a tool using gut bacteria and metabolites to predict if high-risk colon polyps will come back after removal. If you are between 40 and 75 and have had certain types of colon polyps removed, you may be able to help us build better prediction methods.
BeijingAges 40–75 - NCT06801977Recruiting
Chinese lung cancer study for a rare type
This study is collecting information from people with a rare lung cancer called pulmonary lymphoepithelioma-like carcinoma (a type of lung tumor that looks like certain head and neck cancers). It aims to learn more about the disease and how to better treat it.
Foshan, GuangdongAges 18 years+ - NCT06752811RecruitingPhase 3
Testing a new paclitaxel formula for advanced pancreatic cancer
This trial tests a new form of the chemotherapy drug paclitaxel (called polymeric micellar paclitaxel) for people with pancreatic cancer that has spread to other parts of the body (metastatic). It's for those who haven't had any prior treatment for their metastatic cancer, and aims to see if this drug can help control the cancer.
Nanjing, JiangsuAges 18–75 - NCT06762626Recruiting
Comparing two methods of timing a frozen embryo transfer
This trial compares a new method to time a frozen embryo transfer (using a test called ERA) with the standard method. The goal is to find the best time to transfer a high-quality embryo in women who have had multiple failed IVF attempts (recurrent implantation failure).
Hong KongAges 18–40 - NCT06660056RecruitingPhase 1
GC001 injection for returning or growing high-grade brain tumors
This trial tests a new drug, GC001, injected directly into the tumor in people with high-grade gliomas (WHO grade 3 or 4) that have come back or are growing. It may be an option if standard treatments have stopped working.
Beijing, Beijing MunicipalityAges 18 years+ - NCT06672705RecruitingPhase 1
Epcoritamab for post-transplant lymphoma that didn't respond to treatment
This trial tests a new drug called epcoritamab for people whose PTLD (a type of lymphoma that can happen after an organ transplant) has come back or hasn't been helped by standard treatments. The goal is to see if epcoritamab can shrink or control the cancer.
St Louis, MissouriAges 18 years+ - NCT06550921Recruiting
Ablation plus lenvatinib and immunotherapy for advanced liver cancer
This trial tests whether adding a targeted procedure (ablation) to burn away cancer spots, when combined with lenvatinib and an immunotherapy drug (PD-1 inhibitor), can help control liver cancer that has spread to a few places. It's for people whose liver tumors are already responding to treatment.
Beijing, None SelectedAges 18–75 - NCT06523738Recruiting
Studying heart size changes after shock and ablation for AF
This trial looks at how the size of your heart's upper-left chamber (left atrium) changes after a procedure to restore a normal rhythm (cardioversion). It aims to see if these changes can predict whether atrial fibrillation (AF) will come back after a later procedure called radiofrequency ablation.
Chongqing, Chongqing MunicipalityAges 18 years+ - NCT06928584RecruitingPhase 2
Shorter Radiation Plus Immunotherapy for Recurrent Rectal Cancer
This trial tests whether a shorter, higher-dose radiation course (hypofractionated) combined with immunotherapy works better than standard radiation for locally recurrent rectal cancer that hasn't spread elsewhere. It's for people who haven't had chemotherapy or recent pelvic radiation.
Shanghai, Shanghai MunicipalityAges 18–75 - NCT06470217RecruitingPhase 2
Study of tirilizumab plus chemo for advanced oral cancer
This trial tests a combination of immunotherapy (tirilizumab) and two chemotherapy drugs (albumin-bound paclitaxel and cisplatin) for people with advanced but removable oral cancer. The goal is to see if this treatment shrinks the tumor before surgery and improves outcomes.
Shanghai, Shanghai MunicipalityAges 18–75 - NCT06464068RecruitingPhase 2
Immunotherapy plus chemo for first-line advanced extrapulmonary small cell cancer
This trial tests a new combination of durvalumab (an immunotherapy) plus standard chemotherapy for people with advanced small cell carcinoma that started outside the lung and has not been treated before. The goal is to see if this combo works better than chemo alone.
Reggio EmiliaAges 18 years+ - NCT06850545Recruiting
Lu-177 treatment for PSMA-positive metastatic prostate cancer
This trial tests a radioactive drug called Lutetium-177 (Lu-177) that targets and kills prostate cancer cells showing a specific marker (PSMA). It's for men with advanced prostate cancer that has spread and stopped responding to hormone therapy, and who have already tried certain chemotherapy or cannot have it.
Kuopio, Northern SavoniaAges 18 years+ - NCT06182878Recruiting
Supportive care for recurrent pregnancy loss
This study explores a new supportive care program for people who have had multiple pregnancy losses and are pregnant again. It aims to see if extra attention and care can help reduce the risk of another loss.
Bethesda, MarylandAges 18–44 - NCT06320067RecruitingPhase 3
Testing treatments for metastatic hormone-sensitive prostate cancer
This trial tests two newer treatments—targeted radiation (SABR) or a special radioactive drug (Lu-177 PSMA-617)—added to standard hormone therapy for men with prostate cancer that has spread. The goal is to see if these additional treatments help control the cancer better.
BarnsleyAges 18 years+ - NCT06201078RecruitingPhase 2
Second radiation for prostate cancer that returns locally
This trial tests a second round of precise, high-dose radiation (stereotactic body radiotherapy) for men whose prostate cancer has come back only in the prostate after their first radiation treatment. It aims to control the recurrence with fewer side effects.
GliwiceAges 18–80 - NCT06014528RecruitingPhase 2
IN10018 plus liposomal doxorubicin for platinum-resistant ovarian cancer
This trial tests if adding the drug IN10018 to standard chemotherapy (liposomal doxorubicin) can help women with ovarian cancer that has stopped responding to platinum-based treatments. It aims to see if the combination works better than chemotherapy alone.
BeijingAges 18 years+ - NCT06063018RecruitingPhase 2
Testing RC48 and Tislelizumab for recurrent cervical cancer with HER2
This trial tests a combination of two drugs, RC48 and Tislelizumab, for people with recurrent cervical cancer whose tumors have a protein called HER2. The goal is to see if this treatment can help when previous therapy has stopped working.
Beijing, Beijing MunicipalityAges 18–75 - NCT06124976RecruitingPhase 2/Phase 3
A new treatment for low-grade kidney/ureter cancer (ST-02)
This trial tests a new treatment called ST-02 that is given directly into the kidney or ureter to destroy low-grade cancer cells without surgery. It may be an option for people whose cancer has not spread and who are looking for a less invasive treatment.
Vancouver, British ColumbiaAges 18 years+ - NCT05754853RecruitingPhase 3
MRG002 antibody compared with standard chemo for HER2 bladder cancer
This trial studies whether MRG002, a targeted antibody treatment, works better than the patient’s chosen standard chemotherapy. It is for people with HER2-positive advanced or metastatic urothelial (bladder/urinary tract) cancer whose disease has progressed after prior platinum chemotherapy and immunotherapy.
Beijing, Beijing MunicipalityAges 18–75 - NCT05727410RecruitingPhase 2
Nivolumab and chemotherapy before surgery and radiation for salivary cancer
This Phase 2 study tests giving nivolumab plus docetaxel and cisplatin before surgery and radiation for certain resectable, high-grade salivary gland cancers. It aims to shrink or control the cancer early to improve outcomes after treatment.
SeoulAges 19 years+ - NCT05905315RecruitingPhase 2
Vulvar cancer treatment: chemoradiation vs chemotherapy then surgery
This Phase 2 trial compares two treatment approaches for some women with vulvar squamous cell cancer: chemoradiation first, or chemotherapy first followed by surgery. The goal is to see which strategy works better or is safer for tumors that are hard to remove without major pelvic surgery.
AmsterdamAges 18 years+
Hear when a new Recurrent or Metastatic Nasopharyngeal Carcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for recurrent or metastatic nasopharyngeal carcinoma?
- Yes. Clin2 currently lists 2,385 recruiting recurrent or metastatic nasopharyngeal carcinoma studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a recurrent or metastatic nasopharyngeal carcinoma trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a recurrent or metastatic nasopharyngeal carcinoma trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
- Recurrent Nasopharyngeal Carcinoma
- Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma
- Metastatic Nasopharyngeal Carcinoma
- Metastatic Nasopharyngeal Squamous Cell Carcinoma
- Recurrent Nasopharyngeal Squamous Cell Carcinoma
- Nasopharyngeal Carcinoma
- Metastatic Renal Cell Carcinoma
- Nasopharyngeal Carcinoma (NPC)
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.